Nanjing Mingde New Drug Research and Development

Nanjing Mingde New Drug Research and Development is a prominent research and development subsidiary of WuXi AppTec, based in Nanjing, China. The company specializes in the discovery and early-stage development of innovative small molecule therapeutics, particularly focusing on metabolic diseases, oncology, and inflammatory conditions. Operating as a core part of WuXi AppTec's domestic drug discovery ecosystem, Nanjing Mingde leverages an integrated platform to advance internal candidates and collaborative projects with global partners. The company has successfully developed or licensed several high-profile assets, including GLP-1 receptor agonists and THR-beta agonists, some of which have reached late-stage clinical trials or commercialization through partnerships. Its business model combines proprietary R&D with strategic licensing and contract research services to accelerate the delivery of novel medicines to the Chinese and global markets.